1 min read
Add as a preferred source on Google

CG Oncology Shares Rise About 9% After Phase 3 Bladder Cancer Data

The data involved cretostimogene grenadenorepvec, an adjuvant intravesical immunotherapy for non-muscle invasive bladder cancer.

An unmarked treatment vial rests beside a sterile catheter kit / TokenPost.ai
An unmarked treatment vial rests beside a sterile catheter kit / TokenPost.ai

CG Oncology shares rose about 9% in Monday morning trading after the company posted Phase 3 data showing a statistically significant improvement in bladder cancer recurrence risk.

The data covered cretostimogene grenadenorepvec, an adjuvant intravesical immunotherapy for non-muscle invasive bladder cancer.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…